# World's First AI-Designed Vaccine Passes Phase I Human Trial at Cambridge

> In what researchers are calling a first, a vaccine whose active ingredient was designed entirely by AI has passed a Phase I human trial. A team at Cambridge University gave the candidate, designated pEVAC-PS, to 39 healthy volunteers aged 18 to 50 using a needle-free jet that pushes the dose through the skin, and reported no significant side effects on June 5, 2026. The shot triggered immune responses not just against SARS-CoV-2 but also against SARS and related bat coronaviruses seen as future pandemic risks. The significance is less about this one vaccine and more about the method. If AI can propose a viable antigen that then clears human safety testing, the slow and expensive guesswork at the front of vaccine design starts to compress. The spinout behind it, DIOSynVax, is already applying the same approach to universal flu, H5N1 bird flu, and hemorrhagic fevers including Ebola. It is an early but concrete example of AI moving from the lab bench into a real clinic.

_Section: [Daily AI Updates](https://www.wortins.com/daily-ai) · Source: ScienceDaily · Published Tuesday, July 14, 2026_

## Wortins' read

In what researchers are calling a first, a vaccine whose active ingredient was designed entirely by AI has passed a Phase I human trial. A team at Cambridge University gave the candidate, designated pEVAC-PS, to 39 healthy volunteers aged 18 to 50 using a needle-free jet that pushes the dose through the skin, and reported no significant side effects on June 5, 2026. The shot triggered immune responses not just against SARS-CoV-2 but also against SARS and related bat coronaviruses seen as future pandemic risks. The significance is less about this one vaccine and more about the method. If AI can propose a viable antigen that then clears human safety testing, the slow and expensive guesswork at the front of vaccine design starts to compress. The spinout behind it, DIOSynVax, is already applying the same approach to universal flu, H5N1 bird flu, and hemorrhagic fevers including Ebola. It is an early but concrete example of AI moving from the lab bench into a real clinic.

## Source

[Read the full story at ScienceDaily](https://www.sciencedaily.com/releases/2026/06/260605023357.htm)

## Related coverage

- [Clearview AI Is Testing an AI Tool That Would Let Cops Unearth Your Life Online](https://www.wortins.com/story/clearview-ai-is-testing-an-ai-tool-that-would-let-cops-unear-8c573d0e) — [Wired](https://www.wired.com/story/clearview-ai-is-testing-an-ai-tool-that-lets-cops-instantly-unearth-your-online-activity/)
- [Powering AI is an architecture problem](https://www.wortins.com/story/powering-ai-is-an-architecture-problem-15281f16) — [MIT Technology Review](https://www.technologyreview.com/2026/09/10/1141649/powering-ai-is-an-architecture-problem/)
- [Inception launches Mercury 2.5 at 1,107 tokens per second](https://www.wortins.com/story/inception-launches-mercury-2-5-at-1-107-tokens-per-second-7999ed1b) — [TestingCatalog](https://www.testingcatalog.com/inception-launches-mercury-2-5-at-1-107-tokens-per-second/)
- [STAT+: Can AI fix the emergency room?](https://www.wortins.com/story/stat-can-ai-fix-the-emergency-room-a71d00ee) — [STAT](https://www.statnews.com/2026/09/09/scribe-emergency-room-fix-health-care-ai-prognosis/?utm_campaign=rss)
- [Top AI spenders cut per-employee costs by nearly 10 percent in August](https://www.wortins.com/story/top-ai-spenders-cut-per-employee-costs-by-nearly-10-percent--b31ffb0b) — [The Decoder](https://the-decoder.com/top-ai-spenders-cut-per-employee-costs-by-nearly-10-percent-in-august/)
- [Researchers used AI to build a WeChat worm that spreads through phone calls](https://www.wortins.com/story/researchers-used-ai-to-build-a-wechat-worm-that-spreads-thro-8bf3f469) — [The Next Web](https://thenextweb.com/news/wechat-worm-ai-calif-tencent-zero-click)

---

_Curated and written by [Wortins](https://www.wortins.com) — The daily AI briefing. Every story links to its original source; the "Wortins read" on each is our own original analysis. [About Wortins & our editorial approach](https://www.wortins.com/about)._